StockIceMan's Weekly Stock Pick
Week of
May 28, 2007
| Stock: |
IDM Pharma, Inc. |
|
|
| Ticker Symbol: |
IDMI - Nasdaq - Biotechnology |
|
|
| Buy: |
2.50 to 3.00 |
|
|
| Sell: |
5.00 |
|
|
|
Info: |
IDM Pharma, Inc., a
biopharmaceutical company, engages in the
development of products to treat and control
cancer. The company primarily develops product
candidates to destroy residual cancer cells, as
well as product candidates to stimulate an
immune response and prevent tumor recurrence.
Its products include Junovan, an immune system
stimulant, which completed phase III study for
the treatment of osteosarcoma; Bexidem, a
cell-based immunotherapeutic, which is in phase
II trials for the treatment of bladder cancer;
and Uvidem, which is in Phase II clinical trials
for the treatment of melanoma, consists of
dendritophages and melanoma tumor cell lysates.
The company�s products also include EP-2101,
which has multiple tumor-associated CTL epitopes,
is in Phase II trials for the treatment of
non-small cell lung cancer; and Collidem, which
is in Phase I/II trails for the treatment of
Colorectal cancer, consists of dendritophages
and tumor associated antigen peptides. It
operates in the United States and France. IDM
Pharma has collaboration agreements with
sanofi-aventis S.A; Medarex, Inc.; GenPharm
International, Inc.; Novartis; and Biotecnol
S.A. The company is based in Irvine, California. |
|
|
| Financial Info: |
For the fiscal year ended
12/31/2006, revenues rose 32% to $11.3 million.
Net loss fell 40% to $23.5 million. |
|
|
| Key Ratios: |
Current
Ratio: 1.829, Total Debt/Equity: 0.032, Trailing
P/E: N/A, Forward P/E: N/A, Price/Book:
2.95, Price/Sales: 4.00 |
|
|
| Share Info: |
There are 17.96
million shares outstanding with 10.54
million shares in the trading
float. Institutions own
approximately 19.35% of the shares outstanding.
There have been no insider purchases or sales
in the last six months.
Real-Time SEC
Filings
As of 4/10/2007, there were 42,490 shares short.
Net Institutional Buying: 46,164 shares prior to latest
quarter. |
|
|
| Articles: |
Out of the Gate- IDM
Pharma Up
Coverage initiated on IDM
Pharma by Cantor Fitzgerald |
|
